Cologuard's Improved Performance to Accelerate Growth, Analyst Raises Expectations
Portfolio Pulse from Vandana Singh
Exact Sciences Corp announced positive topline results from the BLUE-C study, showing improved performance of next-generation Cologuard. Canaccord Genuity reiterated its Buy rating and increased the price target to $115 from $92. The company expects to achieve positive free cash flow in 2Q23.
June 23, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences' next-generation Cologuard met all study endpoints in the BLUE-C study, leading Canaccord Genuity to raise its price target to $115 from $92.
The positive results from the BLUE-C study indicate improved performance of the next-generation Cologuard, which is expected to accelerate growth for Exact Sciences. Canaccord Genuity's increased price target and Buy rating signal a bullish outlook for the company's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100